Okay, let's tackle this question about the dose of methotrexate for rheumatoid arthritis. First, I need to remember the standard dosing guidelines. Methotrexate is a cornerstone in RA treatment, so this is a key point.

The core concept here is understanding the pharmacological use of methotrexate. Methotrexate is a folic acid antagonist and an antimetabolite. It works by inhibiting dihydrofolate reductase, which is essential for purine synthesis. This leads to reduced proliferation of immune cells, thus decreasing inflammation in RA. The dosing is crucial because too high a dose can lead to toxicity, while too low is ineffective.

The correct answer is likely 7.5-25 mg weekly. That's the standard starting and maintenance dose for RA. It's usually taken once a week, sometimes with folate supplementation to reduce side effects. The options probably include other doses, like daily dosing or higher amounts. Let me think about the wrong options. If an option says 25 mg daily, that's incorrect because daily high-dose MTX is used in cancer, not RA. Another wrong option might be a lower dose, like 2.5 mg weekly, which is too low for RA. Also, higher than 25 mg weekly isn't standard and increases toxicity risk.

Clinical pearls: Remember that methotrexate is weekly for RA, not daily. The dose is titrated up to 25 mg as tolerated. Always check for liver function and folate levels. Also, folic acid is often given to mitigate side effects like mouth sores and gastrointestinal issues.

**Core Concept** Methotrexate is a folic acid antagonist used in rheumatoid arthritis (RA) to suppress excessive immune activity. Its therapeutic dose is carefully calibrated to balance efficacy and toxicity, targeting 7.5–25 mg/week for RA, distinct from higher-dose regimens used in oncology.

**Why the Correct Answer is Right** Methotrexate inhibits dihydrofolate reductase, impairing purine synthesis and reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6). Weekly low-dose methotrexate (7.5–25 mg) achieves sustained immune suppression with minimal hepatic or hematologic toxicity. Dosing is often titrated upward in 2.5–7.5 mg increments based on patient tolerance and response.

**Why Each Wrong Option is Incorrect**
**Option A:** If 2.5 mg/week: This is subtherapeutic and insufficient to modulate RA inflammation.
**Option B:** If 50 mg/week: Exceeds standard RA dosing, increasing risks of hepatotoxicity and bone marrow suppression.
**Option D:** If daily dosing: High-dose daily regimens (used in oncology) cause severe toxicity and are contraindicated in RA.

**Clinical Pearl / High-Yield Fact** Methotrexate is administered **weekly** for RA. Confusion with oncologic high-dose protocols is a common exam trap. Monitor LFTs and consider folic acid supplementation to reduce mucocutaneous side effects.

**Correct Answer: C. 7.5–25 mg/week**

✓ Correct Answer: A. 7.5 - 15 mg/week